Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari Sells 45,042 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 45,042 shares of the company’s stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the completion of the transaction, the chief operating officer now owns 72,363 shares of the company’s stock, valued at $2,207,795.13. This trade represents a 38.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.38, for a total transaction of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.46, for a total value of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $26.41, for a total value of $316,920.00.
• On Monday, April 14th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $20.48, for a total value of $245,760.00.

Kiniksa Pharmaceuticals Trading Up 1.5%

NASDAQ KNSA opened at $30.22 on Thursday. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $17.38 and a 12 month high of $30.69. The stock has a 50 day moving average of $24.80 and a 200-day moving average of $22.08. The company has a market cap of $2.21 billion, a PE ratio of -215.84 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $137.79 million during the quarter, compared to analysts’ expectations of $128.35 million. During the same quarter last year, the company posted ($0.25) earnings per share. The company’s revenue for the quarter was up 72.5% compared to the same quarter last year. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several large investors have recently modified their holdings of KNSA. Nuveen Asset Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock worth $15,737,000 after acquiring an additional 54,361 shares during the period. Wellington Management Group LLP boosted its stake in Kiniksa Pharmaceuticals by 46.3% in the 4th quarter. Wellington Management Group LLP now owns 69,813 shares of the company’s stock valued at $1,381,000 after purchasing an additional 22,096 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Kiniksa Pharmaceuticals by 36.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company’s stock valued at $2,414,000 after buying an additional 32,393 shares in the last quarter. Raymond James Financial Inc. bought a new position in Kiniksa Pharmaceuticals during the 4th quarter worth $3,955,000. Finally, Globeflex Capital L P lifted its holdings in shares of Kiniksa Pharmaceuticals by 217.1% during the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company’s stock worth $1,752,000 after buying an additional 60,656 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Wall Street Zen cut shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 6th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price for the company. Wedbush reissued an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Jefferies Financial Group increased their price objective on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.